A study to find out which is the better drug between tamsulosin and mirabegron in treating patients having ureteric stents for stent related urinary complaints
- Conditions
- Health Condition 1: N201- Calculus of ureter
- Registration Number
- CTRI/2019/11/022115
- Lead Sponsor
- Dr Josef B Pachikara
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients who have underwent semirgid ureteroscopy with DJ stenting.
2. Only patients with uncomplicated ureteric calculi.
3 Patients aged 18 years to 60 years.
1. Patients with growth in Urine culture or having symptomatic urinary tract infection.
2. Patients who may need bilateral stent insertion for acute obstruction / obstructive uropathy
3. Male patients with history of prostatic enlargement, prostatitis or prostatic cancer related lower urinary tract symptoms
4. Females with lower urinary tract symptoms related to any form of urinary incontinence, uterine/cervical/vaginal prolapse, or obstruction related to malignancy.
5. History of chronic or recent α-blocker or analgesic drug use were excluded.
6. Pregnancy,
7. Bleeding disorders,
8. Patients with concomitant other lower tract pathology like bladder cancer, bladder outlet obstruction with or without stones, urethral stricture.
9. Patients with simultaneous renal calculus.
10. Patients who underwent open surgery for ureteric calculi previously.
11. Patients not fulfilling inclusion criteria.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the effect of Tamsulosin and Mirabegron in ureteral stent related symptoms.Timepoint: 2 weeks
- Secondary Outcome Measures
Name Time Method to assess quality of life in patients taking tamsulosin and mirabegron for ureteral stent related symptoms as measured by USSQ quality of life scaleTimepoint: 2 weeks